Reinhardt Marielen, Behnes Michael, Weidner Kathrin, Ayasse Niklas, Lau Felix, Schmitt Alexander, Abel Noah, Dudda Jonas, Bertsch Thomas, Duerschmied Daniel, Akin Ibrahim, Schupp Tobias
Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care, University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany.
Vth Department of Medicine (Nephrology, Hypertensiology, Endocrinology, Rheumatology, Pneumology) & Transplant Center Mannheim, University Hospital Mannheim, Medical Faculty Mannheim, University of Heidelberg, Heidelberg, Germany.
Int J Cardiol. 2025 Feb 15;421:132878. doi: 10.1016/j.ijcard.2024.132878. Epub 2024 Dec 3.
The study investigates the prognostic impact of dyskalemias in patients hospitalized with heart failure with mildly reduced ejection fraction (HFmrEF).
Although dyskalemias represent a common complication in patients with heart failure (HF) and reduced left ventricular ejection fraction (LVEF), data concerning the prevalence and prognostic impact of dyskalemias in HFmrEF is limited.
Consecutive patients with HFmrEF were retrospectively included at one institution from 2016 to 2022. The prognostic impact of potassium levels was assessed comparing patients with potassium levels > 3.3 to ≤4.5 mmol/L, ≤3.3 mmol/L and > 4.5 mmol/L. The primary endpoint was all-cause mortality at 30 days.
2079 patients with HFmrEF and potassium measurement were included (median potassium level: 4.4 mmol/L; mean 4.2 mmol/L). 84 % of patients hospitalized with HFmrEF presented with potassium levels in the norm range, 8 % with hypokalemia and 8 % with hyperkalemia, respectively. The risk of all-cause mortality at 30 days was higher in patients with hyperkalemia compared to patients with normokalemia (7 % vs 4 %; log rank p = 0.026), whereas the presence of hypokalemia (6 %; log rank p = 0.075) was not significantly associated with the risk of 30-days all-cause mortality. Compared to patients with normokalemia, the presence of hyperkalemia was still associated with an increased risk of 30-day all-cause mortality within a multivariable Cox regression analysis (HR = 2.002; 95 % CI 1.004-3.992; p = 0.049).
In patients hospitalized with HFmrEF, hyperkalemia - but not hypokalemia - was independently associated with an increased risk of all-cause mortality at 30 days.
本研究调查了射血分数轻度降低的心力衰竭(HFmrEF)住院患者中血钾异常的预后影响。
尽管血钾异常是心力衰竭(HF)和左心室射血分数(LVEF)降低患者的常见并发症,但关于HFmrEF中血钾异常的患病率和预后影响的数据有限。
2016年至2022年在一家机构对连续性HFmrEF患者进行回顾性纳入。比较血钾水平>3.3至≤4.5 mmol/L、≤3.3 mmol/L和>4.5 mmol/L的患者,评估血钾水平的预后影响。主要终点是30天全因死亡率。
纳入了2079例有血钾测量值的HFmrEF患者(血钾中位数:4.4 mmol/L;均值4.2 mmol/L)。分别有84%的HFmrEF住院患者血钾水平在正常范围,8%为低钾血症,8%为高钾血症。与血钾正常的患者相比,高钾血症患者30天全因死亡风险更高(7%对4%;对数秩检验p = 0.026),而低钾血症(6%;对数秩检验p = 0.075)与30天全因死亡风险无显著关联。在多变量Cox回归分析中,与血钾正常的患者相比,高钾血症的存在仍与30天全因死亡风险增加相关(HR = 2.002;95%CI 1.004 - 3.992;p = 0.049)。
在HFmrEF住院患者中,高钾血症而非低钾血症与30天全因死亡风险增加独立相关。